BioSpace’s Post

Obesity and the associated comorbidities are getting more attention. Take time to read this paper on obesity related clinical research by two of my colleagues

GLP-1s have been one of the biggest stories in pharma of the past year, here's what to keep an eye out for in the future: https://lnkd.in/gSEpqQ4Y #Pharma #Biotech #SciSearch

A drug in development as a weight loss treatment succeeded in a Phase 2 study in a serious liver condition, as the competition in the broader #obesity medicine field pushes ahead. The drug, survodutide, is being developed by the German firm Boehringer Ingelheim and the Danish #biotech Zealand Pharma. #pharmaceuticalindustry #drugdevelopment #pharmaceuticals #obesitymedicine #survodutide #weightloss #clinicaltrials #liverdisease #fibrosis #MASH #biotechnology

The pharmaceutical industry has seen a wave of interest for weight loss drugs like Ozempic and Wegovy. However, obesity is complex, and a personalized approach is key in finding what works best for each patient. Our CEO Mark Bagnall recently spoke with PharmaVoice to discuss how phenotyping is bringing precision medicine to the obesity space and how pharmaceutical companies can benefit from and play a dynamic role in this movement. https://lnkd.in/eay9yqGa #Phenotyping #Obesity #WeightLoss #Ozempic #Wegovy #PharmaTrends

Obesity Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Nano Precision Medical, Bukwang Pharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obesity pipeline constitutes 100+ key companies continuously working towards developing 130+ Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Obesity … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

The 2021 US approval of Novo Nordisk’s breakthrough therapy Wegovy (semaglutide) for obesity transformed the disease landscape, prompting companies to not only develop drugs with a similar mechanism of action (MOA), but also to explore and investigate novel targets. This year, we can expect to see several exciting events for novel obesity pipeline drugs that go beyond targeting GLP-1 receptors. Check out this article for more information on the latest biotech innovations in the obesity drug space. #obesity #biotech #pharmaceuticals #healthcare #innovation Source: https://lnkd.in/egGR6qcW

Obesity Pipeline Report, 2023 Updates: In-depth Analysis into the Clinical Trials, Latest FDA, EMA, and PMDA Approvals, Emerging Drugs, and Growth Prospects | Nano Precision Medical, Bukwang Pharma: (Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Obesity pipeline constitutes 100+ key companies continuously working towards developing 130+ Obesity treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. “Obesity … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Thursday's news of Madrigal Pharmaceutical's FDA approval of Rezdiffra for NASH/MASH represents a significant step forward in the management of this potentially massive new treatment area. With that approval, several other players, with different mechanisms of action, are looking to replicate that success. This post (1 of 2) shows Akero Therapeutics’ recent preliminary Phase 2b data for its MASH drug, efruxifermin, improving its performance (1 stage improvement in fibrosis) against placebo as time progressed. As noted in the article, "efruxifermin is a fusion protein that serves as an analog of fibroblast growth factor 21, or FGF21. This hormone, found in the body, protects against cellular stress and also regulates metabolism." #gastroenterology #hepatology #MASH #clinicaldata #competitiveintelligence

Thoughts on this? >> ACC: Ionis’ rare metabolic disorder drug slides from 100% efficacy, but FDA ambitions unchanged >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #competitivemarketing #healthcare #pharma #biotech #pharmaceutical